Navigation Links
Vioxx Disclosure Emphasizes Need for New Web Resource that Answers Questions About Anti-Epileptic Medication Use
Date:4/17/2008

Prescribing for Better Outcomes Offers Unbiased, Comprehensive Analysis of Drug Research; Site Comes in Response to 2004 Pharmaceutical Suit Against Warner-Lambert

CHAPEL HILL, N.C., April 17 /PRNewswire-USNewswire/ --- Physicians and consumers who want fair and balanced information about the most appropriate uses for prescription medications can now find it using a Web-based resource that provides easily accessible, science-based research about drug uses free from pharmaceutical industry influence.

Prescribing for Better Outcomes, a Web-based educational campaign (http://prescribingforbetteroutcomes.org) designed to provide accurate information about the uses of anti-epileptic drugs for the treatment of bipolar disorder, grew out of a global effort to promote evidence-based research and counter the practice of "off-label marketing," in which drug companies promote uses of their medications that may not be supported by science or approved by the U.S. Food and Drug Administration.

"All patients have unique needs. Sometimes, prescribing a drug for an off-label use is the best option," said Dr. John Oldham, M.D., a psychiatrist and Chief of Staff at The Menninger Clinic and the editor of the Journal of Psychiatric Practice. "But when decisions about off-label prescribing are influenced by explicit and deceptive marketing tactics, it lessens our ability as medical professionals to find the best treatment for individual patients."

Prescribing for Better Outcomes (http://prescribingforbetteroutcomes.org) was launched in direct response to a 2004 lawsuit brought by 50 state attorneys general against pharmaceutical manufacturer Pfizer and its subsidiary, Warner-Lambert. The drug company had been charged with using deceptive marketing tactics to promote off-label sales of its anti-epileptic drug, Neurontin, the brand name for gabapentin. The pervasiveness of Warner-Lambert's off-label marketing techniques was found to increase the likelihood that physicians would prescribe gabapentin for the treatment of bipolar disorder, even though evidence-based research demonstrated that this treatment was largely ineffective.

The Prescribing for Better Outcomes campaign is funded by a portion of the settlement from that landmark case. In addition to the tools and information available at PrescribingforBetterOutcomes.org, the program includes resources for clinical practice and a forthcoming continuing medical education module.

"Deceptive, off-label marketing hurts the public and makes it harder for physicians and other practitioners to give their patients appropriate medical care because they're making decisions based on faulty information," said Tim Carey, M.D., M.P.H., Director of The Cecil G. Sheps Center for Health Services Research at the University of North Carolina at Chapel Hill. "Unfortunately, experience indicates that the practice of off-label marketing extends beyond gabapentin. We hope that Prescribing for Better Outcomes will help physicians to become more aware of the sources and quality of information used to guide patient care."

The Web-based resource PrescribingforBetterOutcomes.org was launched by The Sheps Center. The site will help clinicians and consumers better understand what the research actually shows regarding the efficacy of various antiepileptic drugs, including gabapentin, by providing an unbiased comprehensive analysis of the published research on this class of drugs. The site will later be expanded to include information about other prescription drugs.

"It is unrealistic to expect that medical professionals have time to carefully dissect all of the published research on prescription medication," said Cathy Melvin, Principal Investigator and Director of Child Health Services Research at The Sheps Center. "With access to information that the Prescribing for Better Outcomes program provides, medical professionals will be better informed as they make decisions about patient treatment. The site will also help the public better understand the drugs that have been prescribed to them and allow for a mutually beneficial doctor-patient relationship."


'/>"/>
SOURCE Prescribing for Better Outcomes
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New study may explain Vioxx side-effects
2. Study Points to Cause of Vioxx Heart Risk
3. Vioxx Ban Tied to Rise in Serious GI Trouble
4. The Lanier Law Firm Announces $4.85 Billion National Vioxx Settlement With Merck & Co. Inc.
5. Vioxx Settlement Puts Painkillers Back in the Spotlight
6. Vioxx Settlement Announced
7. Merck Pays More Than $400 Million to Settle Federal, State Medicaid Fraud Investigation Sparked by Qui Tam Whistleblower Case Detailing Marketing Schemes for Vioxx(R), Zocor(R), Several Other Drugs
8. In Post-Vioxx Era, Biologics are Reviving the Arthritis Treatment Market
9. Special Masters Appointed in Program to Resolve U.S. VIOXX(R) Product Liability Lawsuits
10. Key Vioxx Research Was Written by Merck, Documents Allege
11. NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... A new addiction ... at a time when Virginia faces an opioid epidemic. , Last ... increase of 38 percent from 2015, underscoring the need for additional addiction treatment ...
(Date:9/21/2017)... Fort Worth, TX (PRWEB) , ... September 21, ... ... top 50 senior housing operators, announces the acquisition of Isle at Kingwood Assisted ... Isle at Kingwood is an established retirement community with 55 assisted living apartments, ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... the Month, Lewis and Clark College Emeritus Professor of Education Gregory A. Smith ... co-author of Asleep at the Switch: Schoolhouse Commercialism, Privacy, and the Failure ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... of Excellence (CoE) with the latest Artificial Intelligence (AI) thinking, announced today the ... quick and easy access to essential information that offers a more comprehensive understanding ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... as one of the Best Places to Work in the Research Triangle for ... Workplace. Once nominated, a company had to meet a threshold in employee participation--a ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... WASHINGTON , Sept. 8, 2017 ... Mobile MRI Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, ... to Washington, D.C. offering free MRI brain scans to the public.Where:  ... – will be parked at 501 K Street NW, Washington, D.C.What:BTF brings ...
(Date:9/9/2017)... Sept. 9, 2017  Eli Lilly and Company (NYSE: ... secondary endpoint data for lasmiditan, an investigational, oral, first-in-class ... statistically significant improvements compared to placebo in the Phase ... at the 18th Congress of the International Headache Society ... "The data presented today demonstrate lasmiditan,s potential to reduce ...
(Date:9/7/2017)... 2017  For nearly two decades, New Life Agency has been committed ... industry. Today, New Life Agency announces a powerful three-way partnership designed to ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
Breaking Medicine Technology: